Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cariprazine Depot in Schizophrenia, Bipolar I Disorder, and Major Depressive Disorder
NCT07185815Phase 2Recruiting
- Sponsor
- Mapi Pharma
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label trial of cariprazine in schizophrenia, bipolar I disorder and major depressive disorder (MDD) (3 cohorts), sponsored by Mapi Pharma. Primary endpoints: Adverse Events at 24 weeks and Pharmacokinetics at 24 weeks. Started Aug 2025; status: recruiting.
02
Drugs
cariprazine
03
Conditions
schizophreniabipolar I disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07185815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185815.